REGENXBIO Inc. (RGNX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

REGENXBIO Inc. (RGNX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

7.26

0.21 (2.98%)

At close: Jan 15, 2025, 12:59 PM

undefined% (undefined)

Bid	7.25
Market Cap	359.95M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-5.01
PE Ratio (ttm)	-1.45
Forward PE	n/a
Analyst	Buy

Ask	7.28
Volume	871,537
Avg. Volume (20D)	1,235,198
Open	7.40
Previous Close	7.05
Day's Range	7.18 - 7.69
52-Week Range	6.56 - 28.80
Beta	undefined

About RGNX

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, wh...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 17, 2015

Employees 344

Stock Exchange NASDAQ

Ticker Symbol RGNX

Website https://www.regenxbio.com

Analyst Forecast

According to 11 analyst ratings, the average rating for RGNX stock is "Buy." The 12-month stock price forecast is $37, which is an increase of 409.29% from the latest price.

Buy 81.82%

Hold 9.09%

Sell 0.00%

Stock Forecasts

Next Earnings Release

REGENXBIO Inc. is scheduled to release its earnings on Feb 25, 2025, during market hours.
Analysts project revenue of $23.52M, reflecting a 5.88% YoY growth and earnings per share of -1.11, making a -22.38% decrease YoY.

Why Price Moved

1 month ago · Source

+5.4%

REGENXBIO shares are trading higher after the comp... Unlock content with Pro Subscription

2 months ago · Source

+18.66%

Regenxbio shares are trading higher after the company reported better-than-expected Q3 revenue results.

News

2 months ago · seekingalpha.com

REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript

2 months ago · zacks.com

Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates

Regenxbio (RGNX) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.41 per share a year ago.

2 months ago · seekingalpha.com

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Positive updated long-term results from phase I/II/III CAMPSITE study using RGX-121 for the treatment of patients with MPS II. Rolling BLA submission of RGX-121 for the treatment of patients with MPS ...